Why BGPT?
logo

Review Papers Claim by Claim

Check each claim against its experiments, reported results, scope, and stated limitations.Know what the science actually supports before you trust the answer.

Press Enter ↵ to start review



    Explore by Goal












     Quick Explanation


    Bottom line (skeptical, data-grounded)
    The paper reports that multiple imidazole-based OGG1 small-molecule agonists increase OGG1’s overall DNA cleavage rate on 8-oxoG-containing substrates (≥~2-fold for many hits) and that this stimulation tracks with increased AP-lyase activity, while a glycosylase-only OGG1 separation-of-function mutant (KCCK) is not stimulated—suggesting agonist-driven turnover/processing step acceleration rather than faster glycosylase chemistry.
    Key limitation: the cellular work uses a single OGG1-deficient leukemia line under paraquat challenge, so translation to other cell types/in vivo remains unproven.



     Long Explanation


    Paper Review: Small molecule agonists of 8-oxoguanine DNA glycosylase, OGG1
    Paper date: Jan 31, 2026. DOI: 10.64898/2026.01.30.702659.
    One-sentence scientific thesis
    SAR-driven OGG1 agonists increase OGG1 activity on 8-oxoG substrates, and mechanistic separation suggests agonists do not accelerate glycosylase chemistry but instead boost AP lyase turnover, with several compounds also mitigating paraquat-induced oxidative stress phenotypes in OGG1-deficient cells.
    Figure A — EC50 potency landscape (selected reported values)
    EC50 values are from the fluorescence-based DNA cleavage assay on an 8-oxoGua-containing substrate, as reported for several compounds.
    Note: some EC50 values shown here (e.g., F44) come from the detailed supporting tables embedded in the provided full text excerpt; where the excerpt reported “–” or missing fold-change, those entries were omitted from fold-change analyses below.
    Figure B — Potency vs stimulation magnitude (fold at 10 µM)
    Fold-change at a single concentration (10 µM) is not identical to EC50; the paper explicitly notes that stimulation measured in the overall assay does not reveal which kinetic step is accelerated.
    Figure C — Mechanistic logic chain supported by the paper’s assays
    The paper uses multiple assays to test whether stimulation comes from glycosylase chemistry vs AP lyase chemistry vs turnover.
    Table 1 — Reported EC50 (8-oxoGua substrate assay) and selection logic
    Values shown are from the embedded supporting tables / excerpted results for the paper’s fluorescence incision EC50 measurements.
    Compound EC50 (µM) EC50 SD (µM) Fold @ 10 µM (if reported) Potency vs F01
    F401.70.63.7Better
    F022.00.43.8Better
    TH107853.61.2—Better
    F524.91.33.8Better
    F019.10.52.7Reference
    F3911.61.43.7Comparable
    F4311.01.53.3Comparable
    F4118.26.63.5Worse
    F5823.10.42.0Worse
    F2823.06.71.6Worse
    F3836.13.0—Worse
    Mechanism: what the assay logic actually supports
    1) Overall incision stimulation is real—but step localization matters
    The study begins with a fluorescence-based DNA cleavage readout using TAMRA-labeled 17-mers containing an internal 8-oxoGua, and reports that many analogs increase the initial rate relative to a DMSO control (with EC50 values determined by nonlinear regression).
    However, the authors explicitly caution that this “overall catalytic efficiency” readout does not by itself identify which kinetic step is being accelerated.
    2) AP-lyase stimulation is the key shared mechanistic signature
    Using an AP-site-containing substrate (generated via UDG processing), they report that every compound showing stimulation on 8-oxoGua DNA also stimulates the AP-site cleavage rate, and in several cases the stimulation magnitude is comparable to or larger than on the 8-oxoGua substrate.
    Biologically, this is consistent with the broader BER framework where AP-site processing is crucial for downstream completion of repair.
    3) Separation-of-function mutant supports “not glycosylase chemistry”
    The paper uses the separation-of-function OGG1 mutant KCCK, described previously as retaining excision (glycosylase) but eliminating AP lyase activity.
    In this paper, compounds (including multiple F- series agonists and TH10785) show no increase in the sodium hydroxide-terminated gel-based cleavage readout with 8-oxoGua substrate when using KCCK, implying they do not stimulate glycosylase-only chemistry.
    Skeptical read: this does not uniquely exclude agonist effects on DNA binding/release kinetics that could indirectly change the fluorescence overall readout; it does specifically argue against direct acceleration of glycosylase chemistry under the KCCK assay conditions.
    4) Specificity check against overlapping glycosylases
    The paper tests a set of agonists against NEIL1, NTH1, and E. coli Fpg in fluorescence cleavage assays and reports no significant stimulation overall; one compound (F02) is reported to inhibit NEIL1 under the ThyGly substrate condition, supporting that the agonists are not broadly activating all overlapping glycosylases.
    5) Cellular relevance: paraquat challenge in OGG1-deficient Kasumi-1
    The paper uses Kasumi-1 cells (human AML line characterized by reduced nuclear OGG1) and assesses PQ-induced cytotoxicity via AlamarBlue metabolic activity, reporting that agonists alone (at the tested concentration range) are not significantly cytotoxic, while several agonists pre-treated before PQ show protection against PQ-induced decreases in metabolic activity.
    Mechanistic plausibility: paraquat produces mitochondrial superoxide primarily via complex I, consistent with oxidative DNA damage driving OGG1-linked BER requirements.
    Skeptical critique (what could mislead)
    • Assay-step ambiguity in kinetics: while AP-lyase stimulation is supported by AP-site DNA fluorescence assays and KCCK counters glycosylase-chemistry acceleration, the cellular outcomes remain downstream of many events (uptake, off-targets, general stress responses).
    • Single cellular model: the protective phenotype is shown in one OGG1-deficient line (Kasumi-1). This is suggestive but does not establish generality across cell types, mitochondrial contexts, or OGG1 deficiency mechanisms.
    • Separation-of-function mutant assumptions: KCCK is used as a tool; any residual/indirect effects (e.g., altered DNA binding landscapes) could affect interpretation. The paper’s conclusion is therefore best framed as “no stimulation of glycosylase-only chemistry in this assay,” not absolute exclusion of all other kinetic effects.
    • Selectivity could be context-dependent: they report specificity vs NEIL1/NTH1/Fpg and note one inhibitory effect on NEIL1 by F02; this highlights the need for broader off-target profiling beyond the tested glycosylases.
    Disproof targets (what would change the mechanistic story): (i) evidence that agonists accelerate glycosylase chemistry in a more physiological/glycosylase-only measurement regime, (ii) lack of AP lyase stimulation across orthogonal AP-site substrates, or (iii) inability to reproduce PQ protection in additional OGG1-deficient systems with controls for compound uptake/viability.


    Feedback:    

    Updated: April 09, 2026

     BGPT Paper Review


    Study Novelty

    80%

    Novelty is high because the work expands a specific OGG1 agonist scaffold via SAR, then uses a separation-of-function mutant (KCCK) plus orthogonal chemistry readouts (AP-site substrate, GC-MS/MS excision) to argue mechanistic step localization to AP-lyase-driven turnover rather than just overall incision acceleration.


    Scientific Quality

    80%

    Overall strong biochemical logic with multiple orthogonal assays and a specificity check, plus an explicit mechanistic boundary using KCCK. Main quality risks are (i) cellular validation limited to one OGG1-deficient line and one oxidative stress inducer, and (ii) kinetic inference from assay proxies (fluorescence incision rate and gel readouts) rather than single-turnover pre-steady-state kinetics in cells.


    Study Generality

    70%

    The mechanistic finding (AP lyase/turnover linkage for imidazole agonists) is broadly informative for OGG1 modulation, but translation to other scaffolds, other BER contexts, and in vivo remains uncertain because cellular work is constrained to one model and endpoint.


    Study Usefulness

    70%

    Useful as a scaffold/SAR and mechanistic assay framework for future OGG1 agonist design, including a practical “what to measure to localize the mechanism” strategy (overall incision vs AP-site cleavage vs KCCK glycosylase-only).


    Study Reproducibility

    80%

    Methods are relatively explicit (substrate sequences, reaction composition at screening/EC50, time resolution, plate format, EC50 fitting approach, GC-MS/MS conceptual workflow, and gel assay timing). However, detailed reagent concentrations for every step and full supporting info access are not guaranteed in the provided excerpt.


    Explanatory Depth

    80%

    Mechanistic depth is high relative to typical medicinal chemistry papers because it uses step-resolved experimental design: stimulation on 8-oxoGua DNA, stimulation on AP-site DNA, then KCCK non-stimulation to infer the likely enhanced step (AP lyase turnover).


    🎁 Authors: Collect 401 Free Science Tokens (≈ $40.1 USD)

    Claim My Author Tokens

    Use for 100 days of free BGPT access (4 tokens = 1 day) or trade/sell (≈ $40.1 USD)

     Top Data Sources ExportMCP


     Analysis Wizard



    It structures the paper’s extracted EC50 and fold-at-10µM values into a tidy table, computes potency rankings and correlations (where both values exist), then renders Plotly scatter and log-scaled barplots.



     Hypothesis Graveyard


    Strongman claim: “agonists directly accelerate glycosylase chemistry on 8-oxoGua.” This is disfavored by the KCCK glycosylase-only assay showing equivalent product formation with/without agonists.


    Strongman claim: “cellular protection is due to general cytoprotection unrelated to OGG1.” The paper’s specificity assays and mechanistic coherence (AP-lyase stimulation + reduced PQ cytotoxicity pre-treatment effects in OGG1-deficient cells) argue against purely nonspecific protection, though they do not eliminate off-target/system-level effects.

     Science Art


    Paper Review: Small molecule agonists of 8-oxoguanine DNA glycosylase, OGG1 Science Art

     Science Movie


    Make a narrated HD Science movie for this answer ($32 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT






     Trending